Targeted Modulation of the Meningeal Lymphatic Reverse Pathway for Immunotherapy of Breast Cancer Brain Metastases
ACS Nano · 2025
DOI: 10.1021/acsnano.4c15860 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2025. Verfasst von Yanfeng Dai und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Life and Health Sciences, Hainan Province Key Laboratory of One Health, Collaborative Innovation Center of One Health, Hainan University, H…. Hauptthemen laut MEDLINE: Immunotherapy, Brain Neoplasms, Breast Neoplasms, Meninges. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Wuhan National Laboratory for Optoelectronics, Science and Technology Talent Innovation Project in Hainan Province.
Abstract (Originalsprache)
Treatment of tumor brain metastases remains challenging due to the ineffectiveness of drugs in crossing the blood-brain barrier (BBB). Here, we proposed a potential strategy to target and modulate the meningeal lymphatic system for immunotherapy of breast cancer brain metastases (BCBM) through peripheral administration. CT/fluorescence dual-modality imaging demonstrated that the phospholipid nanoprobe (α-PLNPs) through intracisternal magna injection effectively labeled and long-range tracked the meningeal lymphatic pathway from meningeal lymphatic vessels (MLVs) to periphery drainage cervical lymph nodes (CLNs). Interestingly, the reverse pathway from CLNs to MLVs was also successfully labeled with α-PLNPs through cervical subcutaneous injection, facilitating the noninvasive delivery of immunomodulators to the meningeal lymphatics. Given this, we used melittin-carrying α-M-PLNPs to trigger the modulation of the meningeal lymphatic reverse pathway, which effectively prevents BCBM and prolongs the survival of mice through activating the antigen-presenting cells in the CLNs and promoting the migration of CD8+ T cells into the metastatic brain tumors. This study highlights the potential of the meningeal lymphatic reverse pathway for the immunotherapy of BCBM, which holds great promise for central nervous system disease therapy without the need for drug delivery via BBB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life and Health Sciences, Hainan Province Key Laboratory of One Health, Collaborative Innovation Center of One Health, Hainan University, Haikou, Hainan 570228, China.
- State Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Sanya 572024, China.
- Key Laboratory of Biomedical Engineering of Hainan Province, Collaborative Innovation Center of One Health, Hainan University, Sanya 572024, China.
- Britton Chance Center and MoE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan, Hubei 430074, China.
ORCID-Profile: Zhihong Zhang
Förderung
- National Natural Science Foundation of China
- Wuhan National Laboratory for Optoelectronics
- Science and Technology Talent Innovation Project in Hainan Province
- Hainan University Scientific Research Foundation
Zitieren
APA
Dai, Y., Yu, X., Zhao, Y., Wei, J., Lin, D., Wang, J., Zhang, R., Yuan, X., Li, S., Huang, S., Liu, Q., & Zhang, Z. (2025). Targeted Modulation of the Meningeal Lymphatic Reverse Pathway for Immunotherapy of Breast Cancer Brain Metastases. ACS Nano. https://doi.org/10.1021/acsnano.4c15860
Vancouver
Dai Y, Yu X, Zhao Y, Wei J, Lin D, Wang J, et al. Targeted Modulation of the Meningeal Lymphatic Reverse Pathway for Immunotherapy of Breast Cancer Brain Metastases. ACS Nano. 2025. doi:10.1021/acsnano.4c15860
BibTeX
@article{Dai2025,
author = {Dai, Yanfeng and Yu, Xiang and Zhao, Yifan and Wei, Jianshuang and Lin, Dong and Wang, Jialu and Zhang, Ren and Yuan, Xuenan and Li, Sanmu and Huang, Songlin and Liu, Qian and Zhang, Zhihong},
title = {Targeted Modulation of the Meningeal Lymphatic Reverse Pathway for Immunotherapy of Breast Cancer Brain Metastases},
journal = {ACS Nano},
year = {2025},
doi = {10.1021/acsnano.4c15860}
}
EUVIMED